February 8, 2024

Watch: Dyne Therapeutics — Advancing DYNE-251, an Investigational Medicine for DMD (Webinar Recording)

Dyne Therapeutics recently joined PPMD for a community webinar to present initial clinical data from the DELIVER trial of DYNE-251, a next-generation exon skipping investigational product, in individuals with Duchenne who are amenable to exon…

Learn More

January 3, 2024

Dyne Therapeutics Announces Positive Initial Clinical Data from DELIVER Trial in Duchenne Patients

Dyne Therapeutics today announced positive initial clinical data from its DELIVER trial of DYNE-251 in patients with Duchenne who are amenable to exon 51 skipping. Dyne-251 is an exon skipping product that combines a PMO…

Learn More

September 6, 2022

Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251

Dyne has announced that the first participant has been dosed in the Phase 1/2 DELIVER clinical trial of DYNE-251 in participants with Duchenne amenable to skipping exon 51. Dyne-251 is an exon skipping product that combines…

Learn More

July 7, 2022

Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251

Dyne Therapeutics has announced that the FDA has lifted the clinical hold and cleared its Investigational New Drug (IND) application to initiate a clinical trial of DYNE-251 in participants with Duchenne amenable to skipping exon…

Learn More

January 20, 2022

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne

Dyne Therapeutics recently shared that the FDA issued a clinical hold on their Investigational New Drug (IND) application for the Phase I/II study of their exon skipping therapy utilizing a conjugated monoclonal antibody DYNE-251. For…

Learn More

December 3, 2021

Dyne Therapeutics Announced Submission of IND Application to Initiate Clinical Trial of DYNE-251

Dyne Therapeutics, Inc. announced yesterday the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical trial of DYNE-251 in patients with Duchenne muscular dystrophy…

Learn More